share_log

Goldman Sachs Maintains Buy on Kiniksa Pharmaceuticals, Raises Price Target to $32

Benzinga ·  Jul 26, 2023 09:39

Goldman Sachs analyst Paul Choi maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Buy and raises the price target from $22 to $32.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment